261 related articles for article (PubMed ID: 30819918)
1. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
[TBL] [Abstract][Full Text] [Related]
2. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
[TBL] [Abstract][Full Text] [Related]
3. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
Li X; Su Y; Hege K; Madlambayan G; Edwards H; Knight T; Polin L; Kushner J; Dzinic SH; White K; Yang J; Miller R; Wang G; Zhao L; Wang Y; Lin H; Taub JW; Ge Y
Haematologica; 2021 May; 106(5):1262-1277. PubMed ID: 32165486
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
[TBL] [Abstract][Full Text] [Related]
5. The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
Ishikawa C; Mori N
Eur J Haematol; 2020 Dec; 105(6):763-772. PubMed ID: 32780889
[TBL] [Abstract][Full Text] [Related]
6. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
7. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
Mondello P; Derenzini E; Asgari Z; Philip J; Brea EJ; Seshan V; Hendrickson RC; de Stanchina E; Scheinberg DA; Younes A
Oncotarget; 2017 Feb; 8(8):14017-14028. PubMed ID: 28147336
[TBL] [Abstract][Full Text] [Related]
9. Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
Okabe S; Tanaka Y; Moriyama M; Gotoh A
Cancer Chemother Pharmacol; 2020 Feb; 85(2):401-412. PubMed ID: 31901955
[TBL] [Abstract][Full Text] [Related]
10. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M
Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage.
Wang Y; Lin X; Wang Y; Wang G
Invest New Drugs; 2024 Feb; 42(1):70-79. PubMed ID: 38085423
[TBL] [Abstract][Full Text] [Related]
14. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
[TBL] [Abstract][Full Text] [Related]
15. The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.
Qiao X; Ma J; Knight T; Su Y; Edwards H; Polin L; Li J; Kushner J; Dzinic SH; White K; Wang J; Lin H; Wang Y; Wang L; Wang G; Taub JW; Ge Y
Blood Cancer J; 2021 Jun; 11(6):111. PubMed ID: 34099621
[TBL] [Abstract][Full Text] [Related]
16. Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.
Pal S; Kozono D; Yang X; Fendler W; Fitts W; Ni J; Alberta JA; Zhao J; Liu KX; Bian J; Truffaux N; Weiss WA; Resnick AC; Bandopadhayay P; Ligon KL; DuBois SG; Mueller S; Chowdhury D; Haas-Kogan DA
Cancer Res; 2018 Jul; 78(14):4007-4021. PubMed ID: 29760046
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.
Qi W; Zhang W; Edwards H; Chu R; Madlambayan GJ; Taub JW; Wang Z; Wang Y; Li C; Lin H; Ge Y
Cancer Biol Ther; 2015; 16(12):1784-93. PubMed ID: 26529495
[TBL] [Abstract][Full Text] [Related]
18. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
Sadeghi S; Esmaeili S; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bashash D
Turk J Haematol; 2020 Aug; 37(3):167-176. PubMed ID: 32160736
[TBL] [Abstract][Full Text] [Related]
19. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
20. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
